Get the Stockscreener App
89.53
0.61%
0.54
Pre-market:
89.90
0.37
+0.41%
Dexcom Inc stock is traded at $89.53, with a volume of 2.70M.
It is up +0.61% in the last 24 hours and up +3.71% over the past month.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
See More
Previous Close:
$88.99
Open:
$88.99
24h Volume:
2.70M
Relative Volume:
0.79
Market Cap:
$35.11B
Revenue:
$4.15B
Net Income/Loss:
$535.20M
P/E Ratio:
66.81
EPS:
1.34
Net Cash Flow:
$575.20M
1W Performance:
+6.55%
1M Performance:
+3.71%
6M Performance:
+1.34%
1Y Performance:
+39.89%
1-Day Range:
$88.63
$89.76
1-Week Range:
$84.25
$89.76
52-Week Range:
$57.52
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
89.53 | 34.89B | 4.15B | 535.20M | 575.20M | 1.34 |
|
ABT
Abbott Laboratories
|
126.35 | 220.16B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.84 | 157.03B | 18.49B | 2.51B | 2.72B | 1.68 |
|
SYK
Stryker Corp
|
400.69 | 154.21B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
91.97 | 119.08B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.49 | 46.93B | 5.69B | 4.15B | 623.10M | 6.95 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
DexCom (DXCM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
Earnings To Watch: DexCom (DXCM) Reports Q2 Results Tomorrow - Yahoo Finance
Dexcom launches AI-powered meal logging for CGM users - MassDevice
Dexcom Rolls Out AI-Powered Meal Logging for Stelo CGM - Medical Product Outsourcing
Dexcom's AI-Powered Smart Food Logging: A Game-Changer in Glucose Management and Metabolic Health Tech - AInvest
Dexcom adds AI-powered food logging to Stelo glucose monitor By Investing.com - Investing.com India
Dexcom Launches Revolutionary AI-Powered Meal Logging Feature Across Glucose Biosensing Portfolio | DXCM Stock News - GuruFocus
Dexcom Launches Revolutionary AI-Powered Meal Logging Feature Across Glucose Biosensing Portfolio - DexCom Investor Relations
Building a $33B Digital Health Juggernaut | Dexcom Chairman & CEO Kevin Sayer - iHeart
What is the risk reward ratio of investing in DexCom Inc. stockFree Market Volatility Navigation Tips - jammulinksnews.com
What catalysts could drive DexCom Inc. stock higher in 2025Achieve rapid financial growth with expert help - jammulinksnews.com
How Dexcom leverages AI to tackle diabetes - Constellation Research
Why DexCom Inc. stock attracts strong analyst attentionFree Top Growth Stock Recommendations - metal.it
Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact? - MSN
Mizuho Lifts PT on DexCom (DXCM) to $100 From $95, Keeps an Outperform Rating - MSN
What drives DexCom Inc. stock pricePhenomenal wealth increase - PrintWeekIndia
Will DexCom Inc. stock split in the near futureFree Market Volatility Navigation Tips - jammulinksnews.com
Is DexCom, Inc.'s (NASDAQ:DXCM) ROE Of 24% Impressive? - Yahoo Finance
DexCom Takes A Hit As Growth Meets New Headwinds - Finimize
Is DexCom Inc. a good long term investmentFree Investment Case Studies - jammulinksnews.com
What analysts say about DexCom Inc. stockHigh-octane investment gains - jammulinksnews.com
DexCom Inc. Stock Analysis and ForecastFree Popular Stock Recommendations - jammulinksnews.com
We Think DexCom (NASDAQ:DXCM) Can Manage Its Debt With Ease - simplywall.st
DexCom: Delivering Consistent Growth (NASDAQ:DXCM) - Seeking Alpha
Still Too Pricey? Dexcom’s Double-Digit Growth May Not Be Enough (DXCM) - Seeking Alpha
Are Medical Stocks Lagging DexCom (DXCM) This Year? - Yahoo Finance
Why This Beaten-Down Medical Device Stock Could Be Your Best Investment for the Next 5 Years - AOL.com
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dexcom Inc Stock (DXCM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FOLETTA MARK G | Director |
Jul 15 '25 |
Sale |
85.17 |
2,750 |
234,217 |
53,871 |
| Brown Michael Jon | EVP, Chief Legal Officer |
Jul 15 '25 |
Sale |
86.03 |
500 |
43,015 |
94,602 |
0.17%
1.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):